Alzamend Neuro Stock Today
| ALZN Stock | USD 0.95 0.01 1.06% |
PerformanceVery Weak
| Odds Of DistressAverage
|
Alzamend Neuro is selling at 0.95 as of the 19th of March 2025; that is 1.06 percent increase since the beginning of the trading day. The stock's open price was 0.94. Alzamend Neuro has 51 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. The performance scores are derived for the period starting the 17th of February 2025 and ending today, the 19th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 15th of June 2021 | Category Healthcare | Classification Health Care |
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia. The company has 6.6 M outstanding shares of which 52.81 K shares are presently shorted by private and institutional investors with about 0.31 trading days to cover. More on Alzamend Neuro
Moving together with Alzamend Stock
| 0.72 | A | Agilent Technologies | PairCorr |
| 0.89 | ME | 23Andme Holding | PairCorr |
| 0.84 | VANI | Vivani Medical Earnings Call This Week | PairCorr |
Moving against Alzamend Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Alzamend Stock Highlights
| Founder Chairman | Milton III | |||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
Debt LevelsAlzamend Neuro can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Alzamend Neuro's financial leverage. It provides some insight into what part of Alzamend Neuro's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||
Alzamend Neuro (ALZN) is traded on NASDAQ Exchange in USA. It is located in 3480 Peachtree Road NE, Atlanta, GA, United States, 30326 and employs 4 people. Alzamend Neuro is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.2 M. Alzamend Neuro conducts business under Biotechnology sector and is part of Health Care industry. The entity has 6.6 M outstanding shares of which 52.81 K shares are presently shorted by private and institutional investors with about 0.31 trading days to cover.
Alzamend Neuro currently holds about 11.53 M in cash with (8.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.12.
Check Alzamend Neuro Probability Of Bankruptcy
Ownership AllocationAlmost 95.29 percent of Alzamend Neuro outstanding shares are held by general public with 3.0 (percent) owned by insiders and only 1.71 % by other corporate entities.
Check Alzamend Ownership Details
Alzamend Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Activest Wealth Management | 2024-12-31 | 20.0 | |
| Sbi Securities Co Ltd | 2024-12-31 | 18.0 | |
| Advisor Group Holdings, Inc. | 2024-12-31 | 6.0 | |
| Parallel Advisors, Llc | 2024-12-31 | 3.0 | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 3.0 | |
| Susquehanna International Group, Llp | 2024-12-31 | 0.0 | |
| Wells Fargo & Co | 2024-12-31 | 0.0 | |
| Rfg Advisory Group, Llc | 2024-09-30 | 0.0 | |
| Corecap Advisors, Llc | 2024-12-31 | 0.0 | |
| Geode Capital Management, Llc | 2024-12-31 | 33.5 K | |
| Citadel Advisors Llc | 2024-12-31 | 30.6 K |
Alzamend Neuro Historical Income Statement
Alzamend Stock Against Markets
Alzamend Neuro Corporate Management
| Henry Esq | General VP | Profile | |
| Kenneth CPA | Senior Finance | Profile | |
| David Katzoff | Chief Officer | Profile | |
| Stephan Jackman | CEO Director | Profile |
Already Invested in Alzamend Neuro?
The danger of trading Alzamend Neuro is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Alzamend Neuro is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Alzamend Neuro. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Alzamend Neuro is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Alzamend Neuro offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alzamend Neuro's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alzamend Neuro Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alzamend Neuro Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alzamend Neuro. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alzamend Neuro. If investors know Alzamend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alzamend Neuro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Alzamend Neuro is measured differently than its book value, which is the value of Alzamend that is recorded on the company's balance sheet. Investors also form their own opinion of Alzamend Neuro's value that differs from its market value or its book value, called intrinsic value, which is Alzamend Neuro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alzamend Neuro's market value can be influenced by many factors that don't directly affect Alzamend Neuro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alzamend Neuro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alzamend Neuro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alzamend Neuro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.